Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label trial of intraportal autologous bone marrow mononuclear cells to enhance liver regeneration before extended hepatectomy
2009-017793-20Phase 2Completed
- Sponsor
- Andalusian Progress and Health Public Foundation
- Start
- May 2010
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous bone marrow-derived mononuclear cell in Liver lesion (2 arms), sponsored by Andalusian Progress and Health Public Foundation. Primary endpoints: Adverse events, Serious adverse events and 2 more. Started May 2010; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
Liver lesion
Beyond the preview
Go deeper on 2009-017793-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017793-20.